February 29, 2012
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs recommended orphan drug designation for four products including brentuximab vedotin (expected indication: CD30-positive Hodgkin’s lymphoma and anaplastic large-cell lymphoma), which will be submitted for approval by Takeda Pharmaceutical...read more